Cargando…

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease

BACKGROUND: Epoetin beta pegol (continuous erythropoietin receptor activator; C.E.R.A.) is currently widely used for the treatment of anemia associated with chronic kidney disease (CKD). Therapeutic control of anemia is assessed by monitoring haemoglobin (Hb) levels. However, certain qualitative asp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aizawa, Ken, Kawasaki, Ryohei, Tashiro, Yoshihito, Shimonaka, Yasushi, Hirata, Michinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787256/ https://www.ncbi.nlm.nih.gov/pubmed/29374477 http://dx.doi.org/10.1186/s12882-018-0818-4

Ejemplares similares

Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats
por: Hirata, Michinori, et al.
Publicado: (2015)

Epoetin beta pegol ameliorates flow‐mediated dilation with improving endothelial nitric oxide synthase coupling state in nonobese diabetic rats
por: Serizawa, Kenichi, et al.
Publicado: (2017)

Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis
por: Iwasaki, Takahide, et al.
Publicado: (2021)

Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
por: Galli, Luca, et al.
Publicado: (2015)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
por: Ohashi, Naro, et al.
Publicado: (2012)

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
por: Macpherson, Iain RJ, et al.
Publicado: (2009)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
por: Hayashi, Terumasa, et al.
Publicado: (2018)

Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient
por: Shingu, Yasuki, et al.
Publicado: (2020)

A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation
por: Oka, Satoru, et al.
Publicado: (2017)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience
por: Kacarska - Fotevska, Isidora Isidora, et al.
Publicado: (2020)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
por: Davis-Ajami, Mary Lynn, et al.
Publicado: (2014)

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience
por: Kacarska-Fotevska, Isidora, et al.
Publicado: (2019)

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure
por: Jöbsis, Jasper J., et al.
Publicado: (2010)

Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
por: Beiraghdar, Fatemeh, et al.
Publicado: (2015)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Topical ocular delivery of nanoparticles with epoetin beta in Wistar Hannover rats
por: Silva, Beatriz, et al.
Publicado: (2023)

Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2017)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery
por: Silva, Beatriz, et al.
Publicado: (2022)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease
por: Bartnicki, Piotr, et al.
Publicado: (2013)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Visualization of (57)Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging
por: Kihara, Makoto, et al.
Publicado: (2017)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Erythrocyte Catalase Activity in More Frequent Microcytic Hypochromic Anemia: Beta-Thalassemia Trait and Iron Deficiency Anemia
por: Lazarte, Sandra Stella, et al.
Publicado: (2015)

The resistance to methoxy polyethylene glycol-epoetin beta in anemic patients of end-stage renal disease
por: Abood, Sattar J., et al.
Publicado: (2023)

Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease
por: Eisenga, Michele F., et al.
Publicado: (2019)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
por: Casadevall, Nicole, et al.
Publicado: (2017)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
por: Irrera, Natasha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4jf5tbf1959m4rs47nkbjqqn83